	US 12,419,959 B2
	Dermal skin protectant and carrier
Mark A. Latta, Omaha, NE (US)
Assigned to Inspired Material Strategies, LLC, Omaha, NE (US)
Filed by Inspired Material Solutions, LLC, Omaha, NE (US)
Filed on May 23, 2023, as Appl. No. 18/322,065.
Application 18/322,065 is a continuation of application No. 17/303,915, filed on Jun. 10, 2021, granted, now 11,690,916.
Application 17/303,915 is a continuation of application No. 16/674,895, filed on Nov. 5, 2019, granted, now 11,071,786, issued on Jul. 27, 2021.
Claims priority of provisional application 62/846,763, filed on May 13, 2019.
Claims priority of provisional application 62/755,719, filed on Nov. 5, 2018.
Prior Publication US 2023/0293694 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/34 (2017.01); A61K 8/27 (2006.01); A61K 8/92 (2006.01); A61K 31/138 (2006.01); A61K 31/14 (2006.01); A61K 31/195 (2006.01); A61K 31/245 (2006.01); A61K 31/352 (2006.01); A61K 31/4174 (2006.01); A61K 31/4425 (2006.01); A61K 31/5375 (2006.01); A61K 31/573 (2006.01); A61K 31/60 (2006.01); A61K 31/635 (2006.01); A61K 31/7036 (2006.01); A61K 31/7048 (2006.01); A61K 33/38 (2006.01); A61K 38/12 (2006.01); A61K 38/36 (2006.01); A61K 38/48 (2006.01); A61Q 3/00 (2006.01); A61Q 17/00 (2006.01)

CPC A61K 47/34 (2013.01) [A61K 8/27 (2013.01); A61K 8/922 (2013.01); A61K 31/138 (2013.01); A61K 31/14 (2013.01); A61K 31/195 (2013.01); A61K 31/245 (2013.01); A61K 31/352 (2013.01); A61K 31/4174 (2013.01); A61K 31/4425 (2013.01); A61K 31/5375 (2013.01); A61K 31/573 (2013.01); A61K 31/60 (2013.01); A61K 31/635 (2013.01); A61K 31/7036 (2013.01); A61K 31/7048 (2013.01); A61K 33/38 (2013.01); A61K 38/12 (2013.01); A61K 38/363 (2013.01); A61K 38/4833 (2013.01); A61Q 3/00 (2013.01); A61Q 17/00 (2013.01); A61Q 17/005 (2013.01)]

22 Claims

1. A dimethicone-based delivery composition comprising: a first dimethicone material having a viscosity of between about 1,000 cP and 25,000 cP, a second dimethicone material having a viscosity of between about 2.0 million cP and 3.0 million cP, and at least one active agent wherein the concentration of the first dimethicone material is between 50% and 99% of the weight of the dimethicone-based delivery composition and the concentration of the second dimethicone material is between 5% and 50% of the weight of the dimethicone-based delivery composition.